Evidence map›Paper›PMID 24333515›Full record

Trial reportThe Journal of urology2014

Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy.

Ardeshir R Rastinehad, Baris Turkbey, Simpa S Salami, Oksana Yaskiv, Arvin K George, Mathew Fakhoury, Karin Beecher, Manish A Vira, Louis R Kavoussi, David N Siegel and 2 more

Open access · greenAbstract readClinical Trial, Phase IIIComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 4 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016
    Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. MRI-targeted prostate biopsy: the next step forward!Medicine and pharmacy reports · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ardeshir R RastinehadArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland. Electronic address: arastine@nshs.edu.
Baris TurkbeyArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Simpa S SalamiArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Oksana YaskivArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Arvin K GeorgeArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Mathew FakhouryArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Karin BeecherArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Manish A ViraArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Louis R KavoussiArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
David N SiegelArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Robert VillaniArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Eran Ben-LeviArthur Smith Institute for Urology and Departments of Radiology and Interventional Radiology and Pathology, Hofstra North Shore-Jewish School of Medicine, New Hyde Park, New York, and Molecular Imaging Program (BT), National Institutes of Health, Bethesda, Maryland.
Arthur Smith Institute for Urology · USNational Institutes of Health · US

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Intramural NIH HHS ZIA BC010655
6 · The paper itself

Abstract

purposeGiven the limitations of prostate specific antigen and standard biopsies for detecting prostate cancer, we evaluated the cancer detection rate and external validity of a magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy system used at the National Institutes of Health. MATERIALS AND

methodsWe performed a phase III trial of a magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy system with participants enrolled between 2012 and 2013. A total of 153 men consented to the study and underwent 3 Tesla multiparametric magnetic resonance imaging with an endorectal coil for clinical suspicion of prostate cancer. Lesions were classified as low or moderate/high risk for prostate cancer. Magnetic resonance imaging/transrectal ultrasound fusion guided biopsy and standard 12-core prostate biopsy were performed and 105 men were eligible for analysis.

resultsMean patient age was 65.8 years and mean prostate specific antigen was 9.5 ng/ml. The overall cancer detection rate was 62.9% (66 of 105 patients). The cancer detection rate in those with moderate/high risk on imaging was 72.3% (47 of 65) vs 47.5% (19 of 40) in those classified as low risk for prostate cancer (p<0.05). Mean tumor core length was 4.6 and 3.7 mm for fusion biopsy and standard 12-core biopsy, respectively (p<0.05). Magnetic resonance imaging/transrectal ultrasound fusion guided biopsy detected prostate cancer that was missed by standard 12-core biopsy in 14.3% of cases (15 of 105), of which 86.7% (13 of 15) were clinically significant. This biopsy upgraded 23.5% of cancers (4 of 17) deemed clinically insignificant on 12-core biopsy to clinically significant prostate cancer necessitating treatment.

conclusionsMagnetic resonance imaging/transrectal ultrasound fusion guided biopsy can improve prostate cancer detection. The results of this trial support the external validity of this platform and may be the next step in the evolution of prostate cancer management.

Indexed as

AdultAgedAged, 80 and overBiopsy, Large-Core NeedleDiagnosis, DifferentialHumansImage-Guided BiopsyMagnetic Resonance Imaging, InterventionalMaleMiddle AgedNeoplasm GradingProstatic NeoplasmsReproducibility of ResultsRetrospective StudiesUltrasonography, Interventionalbiopsymagnetic resonance imagingprostateprostatic neoplasmsultrasonography

Identifiers

PMID24333515
PMCPMC8374473
OpenAlexW2153860297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.